Research has shown that PD-L1, which can inhibit CD8+ T-cell effector function by interacting with PD-1, is expressed on many types of tumor cells, tumor-associated macrophages (TAMs), and other cells in the tumor immune microenvironment 5. This evidence concerns the gene CD274 and neoplasm.